The tissue-specific metabolic effects of the PPARα agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study.
de Wit-Verheggen VHW, Vanweert F, Raiko J, Liénard V, Schaart G, Gemmink A, Nascimento EBM, Hesselink MKC, Wildberger JE, Wierts R, Joris PJ, Haas J, Montaigne D, Staels B, Phielix E, Schrauwen P, Schrauwen-Hinderling VB, van de Weijer T.
de Wit-Verheggen VHW, et al. Among authors: montaigne d.
Obesity (Silver Spring). 2023 Oct;31(10):2493-2504. doi: 10.1002/oby.23874. Epub 2023 Sep 5.
Obesity (Silver Spring). 2023.
PMID: 37670579
Clinical Trial.